The occurrence of malignant thyroid lesions in patients after radioiodine treatment due to benign thyroid diseases

Endokrynologia Polska

Volumn 61, Issue 5, 2010, Pages 454-457

  Listewnik, Maria H ^a   Birkenfeld, Bozena ^a   Chosia, Maria ^a   Elbl, Bogumiła ^a   Niedziałkowska, Krystyna ^a   Sawrymowicz, Marek ^a  

^a POMERANIAN MEDICAL UNIVERSITY   (Poland)

Author keywords

131I therapy; Craves' disease; Hyperthyroidism; Nodular goiter; Thyroid neoplasm

Indexed keywords

IODINE 131; RADIOACTIVE IODINE;

ADULT; AGED; ARTICLE; ASPIRATION BIOPSY; CANCER RISK; CLINICAL EXAMINATION; ECHOGRAPHY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; ONCOCYTOMA; RADIOISOTOPE THERAPY; THYROID CANCER; THYROID DISEASE; THYROID FOLLICULAR CARCINOMA; THYROID FUNCTION TEST; THYROID PAPILLARY CARCINOMA;

ADENOCARCINOMA, FOLLICULAR; AGED; BIOPSY, FINE-NEEDLE; CAUSALITY; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; IODINE RADIOISOTOPES; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; THYROID DISEASES; THYROID NEOPLASMS;

EID: 78649986925     PISSN: 0423104X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Dobyns BM, Sheline GE, Workman JB et al. Malignant and Benign Neoplasm Treated for Hyperthyroidism: A Report of Cooperative Thyrotoxicosis Therapy Follow-up Study. J Clin Endocrinol Metab 1974; 38: 976-998.
2. Chatal J-F, Hoefnagel CA. Radionuclide therapy. Lancet 1999; 354: 931-935.
3. Radioiodine in the management of benign thyroid disease: clinical guidelines. Report of a Working Party. London RCP 2007.
4. Weetman AP, Radioiodine treatment for benign thyroid diseases. Clinical Endocrinology 2007; 66: 757-764. (Pubitemid 47024277)
5. Hermus AR, Huysmans DA. Treatment of Benign Nodular Thyroid Disease. N Engl J Med 1998; 338: 1438-1447. (Pubitemid 28221986)
6. Cooper DS, Doherty GM, Haugen BR et al. Revised management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009; 19: 1167-1214.
7. 131I) - recommendations. Standardy Medyczne 2004; 9: 908-911.
8. Metso S, Auvinen A, Huhtala H et al. Increased cancer incidence after radioiodine treatment for hyperthyroidism. Cancer; 2007; 109: 1972-1979.
9. Luicignani G. Long-term risk in hyperthyroid patients treated with radioiodine: is there anything new? Eur J Nucl Med Mol Imaging 2007; 34: 1504-1509.
10. Jastrzȩbska H, Gietka-Czernel M, Zgliczyński S. Therapy of benign thyroid disease with Iodine-131. Endokrynol Pol 2003; 54: 187-194.
11. Mumtaz M, Lin LS, Hui KC et al. Radioiodine 1-131 for the Therapy of Graves' Disease. MJMS 2009; 16: 25-33.
12. 131I w przebiegu łagodnych chorób tego gruczołu. Endokrynol Pol 2006; 57 (Suppl. A): 1-6.
13. 131I therapy due to benign thyroid diseases. Polish J of Environ Stud 2007; 16 (Suppl.): 35-38.
14. EANM Procedure Guidelines for Therapy with Iodine-131. Eur J Nucl Med 2003; 30: BP27-BP31.
15. Listewnik MH. Analysis of factors affecting treatment results for toxic goiter with radioactive 1311. Ann Med Sterin 2000; 46: 109-121.
16. Willemsen UF, Knesewitch P, Kresig T et al. Functional results of radioiodine therapy with a 300 GY absorbed dose in Graves' disease. EJNM&MI 1993; 20: 1050-1055.
17. Reiners C, Schneider P Radioiodine therapy of thyroid autonomy. EJNM&MI 2002; 29: 471-478.
18. Holm LE, Hall P, Wiklund K et al. Cancer risk after iodine-131 therapy for hyperthyroidism. J Natl Cancer Inst 1991; 83: 1072-1077.
19. Franklyn J, Sheppard M. Maisonneuve P. Thyroid Function and Mortality in Patients Treated for Hyperthyroidism. JAMA 2005; 294: 71-80. (Pubitemid 41002841)
20. Ron E, Doody MM, Becker DV et al. Cancer mortality following treatment for adult hyperthyroidism. JAMA 1998; 280: 347-355.
21. Angusti T, Codegone A, Pellerito R. Thyroid Cancer Prevalence after Radioiodine Treatment of Hyperthyroidism. JNM 2000; 41: 1006-1008.
22. Górowski T, Gabryelewicz MB, Jastrzȩbska H. Rak anaplastyczny po leczeniu "gora̧cego" nadczynnego guzka tarczycy radiojodem. Endokrynol Pol 1992; 43: 308-313.